Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

Lipson, Evan J; Lilo, Mohammed T; Ogurtsova, Aleksandra; Esandrio, Jessica; Xu, Haiying; Brothers, Patricia; Schollenberger, Megan; Sharfman, William H; Taube, Janis M

Lipson, Evan J; Lilo, Mohammed T; Ogurtsova, Aleksandra; Esandrio, Jessica; Xu, Haiying; Brothers, Patricia; Schollenberger, Megan; Sharfman, William H; Taube, Janis M.

Afiliação

Lipson EJ; Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Lilo MT; Melanoma and Cancer Immunology Programs, Johns Hopkins University School of Medicine, 1550 Orleans Street, Room 507, Baltimore, MD 21231 USA.
Ogurtsova A; Department of Pathology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Esandrio J; Department of Dermatology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Xu H; Department of Pathology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Brothers P; Department of Dermatology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Schollenberger M; Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Sharfman WH; Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.
Taube JM; Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Baltimore, MD USA.

J Immunother Cancer ; 5: 23, 2017.

Article em En | MEDLINE | ID: mdl-28344809

Assuntos

Anticorpos Monoclonais Humanizados/administração & dosagem; Antígeno B7-H1/imunologia; Carcinoma Basocelular/tratamento farmacológico; Receptor de Morte Celular Programada 1/imunologia; Adulto; Idoso; Anticorpos Monoclonais/administração & dosagem; Anticorpos Monoclonais/efeitos adversos; Anticorpos Monoclonais Humanizados/efeitos adversos; Antígeno B7-H1/antagonistas & inibidores; Carcinoma Basocelular/genética; Carcinoma Basocelular/imunologia; Carcinoma Basocelular/patologia; Feminino; Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos; Proteínas Hedgehog/antagonistas & inibidores; Proteínas Hedgehog/genética; Humanos; Linfócitos do Interstício Tumoral/efeitos dos fármacos; Masculino; Pessoa de Meia-Idade; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Transdução de Sinais/efeitos dos fármacos; Microambiente Tumoral/efeitos dos fármacos; Microambiente Tumoral/imunologia

Palavras-chave

Anti-PD-1; Basal cell carcinoma; Hedgehog; PD-L1; Pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Basocelular / Anticorpos Monoclonais Humanizados / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google